Caring for the orphan's orphan: Treatment of patients with portopulmonary hypertension

European Respiratory Journal

Volumn 30, Issue 6, 2007, Pages 1038-1040

  Kawut, S M ^a  

^a PH 8E ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ILOPROST;

AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HIGH RISK POPULATION; HUMAN; LIVER DYSFUNCTION; OUTCOME ASSESSMENT; PATIENT CARE; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; ILOPROST; PATIENT CARE; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 38849184191     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00113407     Document Type: Editorial

References (12)

1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
2. Provencher S, Herve P, Jais X, et al. Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
3. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102.
4. Herve P, Le Pavec J, Sztrymf B, Decante B, Savale L, Sitbon O. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 141-159.
5. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111.
6. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875-885.
7. Sussman N, Kaza V, Barshes N, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006; 6: 2177-2182.
8. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648.
9. Vandenbroucke JP. Analytic approaches to observational studies with treatment selection bias. JAMA 2007; 297: 2077-2078.
10. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267-271.
11. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355-1362.
12. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344.